US · Healthcare · Biotechnology
EPS came in at -0.91 against a street estimate of -0.80 — a miss of 13.7%.
Analysts rate Cybin Inc. a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $40.03.
| Fund | Stake |
|---|---|
| VR Adviser, LLC | 5.27% |
| Orbimed Advisors LLC | 4.48% |
| Adage Capital Partners Gp LLC | 4.19% |
| Millennium Management LLC | 3.60% |
| Rosalind Advisors, Inc. | 2.68% |
| Sphera Funds Management Ltd. | 2.22% |
| DCF Advisers, LLC | 1.96% |
| Sio Capital Management, LLC | 1.78% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • This Form 6-K filing from Helus Pharma Inc. is dated October 8, 2026. • The filing contains one exhibit: a news release dated | 2026-10-08 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Helus Pharma Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 5, 2026. • The filing covers the m | 2026-10-05 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Cybin Inc. legally changed its name to Helus Pharma Inc. effective October 1, 2026. • Shareholders approved the name change at th | 2026-10-02 |
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • Helus Pharma Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • The filing was dated | 2026-10-01 |
| Quarterly results (6-K) · Q1 FY2027 HEADLINE NUMBERS • 107 shareholders attended or voted by proxy at the September 22, 2026 meeting, representing 46,452,598 shares, or 63.58% of shares | 2026-09-23 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • The filing is a Form 6-K submitted by Cybin Inc. for September 2026. • The filing date is September 21, 2026. • The document con | 2026-09-22 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • Helus Pharma announced four poster presentations on HLP003 at Psych Congress 2026, held September 15–19, 2026. • Three presentati | 2026-09-21 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • Helus Pharma (formerly Cybin Inc.) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. • CEO Michael | 2026-09-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cybin Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.